Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

321 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates.
Denton PW, Othieno F, Martinez-Torres F, Zou W, Krisko JF, Fleming E, Zein S, Powell DA, Wahl A, Kwak YT, Welch BD, Kay MS, Payne DA, Gallay P, Appella E, Estes JD, Lu M, Garcia JV. Denton PW, et al. Among authors: fleming e. J Virol. 2011 Aug;85(15):7582-93. doi: 10.1128/JVI.00537-11. Epub 2011 May 18. J Virol. 2011. PMID: 21593172 Free PMC article.
Efficacy and safety of dostarlimab in combination with chemotherapy in patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer in a phase 3, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Powell MA, Cibula D, O'Malley DM, Boere I, Shahin MS, Savarese A, Chase DM, Gilbert L, Black D, Herrstedt J, Sharma S, Kommoss S, Gold MA, Thijs AM, Ring K, Bolling MF, Buscema J, Gill SE, Nowicki P, Nevadunsky N, Callahan M, Willmott L, McCourt C, Billingsley C, Ghamande SA, He Z, Balas MM, Stevens S, Fleming E, Mirza MR. Powell MA, et al. Among authors: fleming e. Gynecol Oncol. 2024 Nov 11;192:40-49. doi: 10.1016/j.ygyno.2024.10.022. Online ahead of print. Gynecol Oncol. 2024. PMID: 39531903
Basic helix-loop-helix transcription factor BHLHE22 monoallelic and biallelic variants cause a neurodevelopmental disorder with agenesis of the corpus callosum, intellectual disability, tone and movement abnormalities.
Le C, Argilli E, George E, Kalaycı T, Uyguner ZO, Karaman B, Demirören T, DiTroia S, Heron D, Sabatier I, Rodan LH, Girisha KM, Radhakrishnan P, Saunders C, Sullivan B, Fleming E, Alvi JR, Sultan T, Houlden H, Efthymiou S, Sacoto MJG, Goodman M, Pierron L, De Sainte-Agathe JM, Durr A, Sherr EH. Le C, et al. Among authors: fleming e. medRxiv [Preprint]. 2024 Dec 17:2024.10.11.24312856. doi: 10.1101/2024.10.11.24312856. medRxiv. 2024. PMID: 39502664 Free PMC article. Preprint.
Safety of dostarlimab in combination with chemotherapy in patients with primary advanced or recurrent endometrial cancer in a phase III, randomized, placebo-controlled trial (ENGOT-EN6-NSGO/GOG-3031/RUBY).
Auranen A, Powell MA, Sukhin V, Landrum LM, Ronzino G, Buscema J, Bauerschlag D, Lalisang R, Bender D, Gilbert L, Armstrong A, Safra T, Nevadunsky N, Sebastianelli A, Slomovitz B, Ring K, Coleman R, Podzielinski I, Stuckey A, Teneriello M, Gill S, Pothuri B, Willmott L, Sharma S, Dabrowski C, Antony G, Stevens S, Mirza MR, Fleming E. Auranen A, et al. Among authors: fleming e. Ther Adv Med Oncol. 2024 Sep 28;16:17588359241277656. doi: 10.1177/17588359241277656. eCollection 2024. Ther Adv Med Oncol. 2024. PMID: 39346117 Free PMC article.
Patient-reported outcomes in the subpopulation of patients with mismatch repair-deficient/microsatellite instability-high primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy compared with chemotherapy alone in the ENGOT-EN6-NSGO/GOG3031/RUBY trial.
Valabrega G, Powell MA, Hietanen S, Miller EM, Novak Z, Holloway R, Denschlag D, Myers T, Thijs AM, Pennington KP, Gilbert L, Fleming E, Zub O, Landrum LM, Ataseven B, Gogoi R, Podzielinski I, Cloven N, Monk BJ, Sharma S, Herzog TJ, Stuckey A, Pothuri B, Secord AA, Chase D, Vincent V, Meyers O, Garside J, Mirza MR, Black D. Valabrega G, et al. Among authors: fleming e. Int J Gynecol Cancer. 2025 Jan 6:ijgc-2024-005484. doi: 10.1136/ijgc-2024-005484. Online ahead of print. Int J Gynecol Cancer. 2025. PMID: 39322611
321 results